<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639635</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS1160</org_study_id>
    <nct_id>NCT04639635</nct_id>
  </id_info>
  <brief_title>CNGB1 and Allied Disorders</brief_title>
  <official_title>Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universität Tübingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>La Fondation Voir et Entendre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and&#xD;
      associated inborn errors in metabolism are causes of retinal disease that causes progressive&#xD;
      loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness&#xD;
      associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be&#xD;
      caused by mutations in a number of different genes. Treatment by gene therapy could prevent&#xD;
      blindness in cases of inherited retinal dystrophies including RP. In the future RP due to&#xD;
      mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor&#xD;
      degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of&#xD;
      opportunity for the identification of patients and initiation of treatment. Our efforts are&#xD;
      directed toward developing gene therapy as a treatment. To this end, our objective is to&#xD;
      better understand the disease process of CNGB1-RP and other allied inherited disorders so&#xD;
      that we can develop clinical tests to measure the outcomes of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>We will be looking to identify what the best outcome measurements will be for CNGB1-RP in order to use these measurements in a future clinical trial.</measure>
    <time_frame>2 days, 1 time per year, for 3 years</time_frame>
    <description>Both structural imaging and functional tests will be used to characterize the natural history progression of CNGB1-RP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medmont Dark Adapted Chromatic (DAC) Automated Perimeter</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Full-field ERG (ISCEV Protocol)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography (OCT)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fundus Autofluorescence (FAF)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Near-infrared fundus autofluorescence (NIR-AF)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative Fundus Autofluorescence (qAF)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected Visual Acuity (BCVA)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Ophthalmic Exam</measure>
    <time_frame>2 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color Fundus Photos</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAIA Microperimetry</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
    <description>if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIDEK Microperimetry</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
    <description>if available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goldman Kinetic Visual Field</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light-adapted Static Perimetry</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Panel D-15 Colour Vision (desat.)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dark-adapted Chromatic Perimetry</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field Stimulus Testing (FST)</measure>
    <time_frame>1 time per year, for 3 years</time_frame>
    <description>Optional</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Demographics/medical history</measure>
    <time_frame>1 time only at baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Concomitant medications/adverse events</measure>
    <time_frame>1 time only at baseline</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinitis Pigmentosa Associated With CNGB1 Mutations</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention, this is a natural history progression study</intervention_name>
    <description>The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are expected to present to the clinic at all age groups; enrollment of subjects&#xD;
        &lt;18 years of age will be obtained by informed consent in the company of a parent or legal&#xD;
        guardian. There will also be no gender-or ethnic/racial specific inclusion criteria. The&#xD;
        enrollment of non-English speaking subjects is not expected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CNGB1-associated RP by study physician, who are trained retinal&#xD;
             specialists in the university clinic&#xD;
&#xD;
          -  Must be able to commit to 4 follow-up study visits (3 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Stephen H. Tsang</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen H Tsang, Md, PhD</last_name>
      <phone>212-342-1186</phone>
      <email>sht2@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Procopio, CGC</last_name>
      <phone>267-733-9681</phone>
      <email>rprocopio@willseye.org</email>
    </contact>
    <contact_backup>
      <last_name>Tobin BT Thuma, DO</last_name>
      <phone>215-928-3240</phone>
      <email>tthuma@willseye.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Audo, MD, PhD</last_name>
      <phone>+33 1 40 02 14 30</phone>
      <email>isabelle.audo@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille Andrieu, MD</last_name>
      <phone>+33 1 40 02 14 51</phone>
      <email>candrieu@15-20.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle Audo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Priglinger, PD Dr.</last_name>
      <phone>+49 (0)89 4400 53717</phone>
      <email>claudia.priglinger@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Stylianos Michalakis, PhD</last_name>
      <phone>+49 (0)89 4400 53083</phone>
      <email>stylianos.michalakis@med.lmu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Maximilian Gerhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls University Tubingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Kuehlewein, MD</last_name>
      <phone>+49 07071 29-88088</phone>
      <email>laura.kuehlewein@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Katarina Stingl, MD</last_name>
      <phone>+49 7071 29 87421</phone>
      <email>katarina.stingl@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Eberhart Zrenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona D Esposti, MD</last_name>
      <phone>(+44) 207 566 2263</phone>
      <email>s.esposti@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Omar Mahroo, PhD</last_name>
      <phone>(+44) 207 566 2263</phone>
      <email>o.mahroo@ucl.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Simona D Esposti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Stephen H. Tsang</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>CNGB1</keyword>
  <keyword>Natural Progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

